Journal of Clinical Medicine (Feb 2024)

Immunological Profiles in Parry–Romberg Syndrome: A Case–Control Study

  • Irma Saulle,
  • Antonio Gidaro,
  • Mattia Donadoni,
  • Claudia Vanetti,
  • Alessandra Mutti,
  • Maria Eva Romano,
  • Mario Clerici,
  • Chiara Cogliati,
  • Mara Biasin

DOI
https://doi.org/10.3390/jcm13051219
Journal volume & issue
Vol. 13, no. 5
p. 1219

Abstract

Read online

Background: Parry–Romberg syndrome (PRS) is a rare craniofacial disorder. The aim of this study is to provide information on the immunological profile of this pathology. Since PRS can be included in a wider spectrum of sclerodermic diseases, we propose a case–control study comparing a patient affected by PRS with one with a diagnosis of scleroderma, herein used as control (CTR). Methods: B lymphocyte, T lymphocyte, and monocyte phenotypes and functions were assessed by flow cytometry in influenza (Flu)- or anti cluster differentiation (CD)3/CD28-stimulated peripheral blood mononuclear cells (PBMCs). Cytokine concentration was evaluated as well in PBMC supernatants, plasma, and saliva by Luminex assay. Results: T and B lymphocytes were similarly activated in unstimulated PRS and CTR cells but differed following antigen stimulation. T helper (Th)17 lymphocytes were expanded in PRS compared to CTR; this increase correlated with higher interleukin (IL)-17 concentration. Conclusions: Our case–control study is the first to compare the immunological profiles of PRS and scleroderma patients. The higher percentage of Th17 cells in PRS suggests the use of anti-IL17 receptor monoclonal antibody in this rare disease; however, further studies with larger numbers of patients are needed to confirm our findings.

Keywords